Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03330197 : A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG
PhasePhase 1
AgesMin: N/A Max: 21 Years
Inclusion Criteria:

1. Male or female subjects ? 21 years-of-age with the demonstrated ability to swallow
capsules whole and who are willing to provide access to previously obtained biopsy

2. Provision of written informed consent and assent, when applicable, for tumor
resection, stereotactic surgery, tumor biopsy, sample collection, and/or treatment
with study drug prior to undergoing any study-specific procedures

3. Arm 1: Evidence of recurrent or progressive supratentorial tumor, which has shown a >
25% increase in bi dimensional measurements by MRI or is refractory with significant
neuro deterioration that is not otherwise explained with no known curative therapy.

Arm 2: Clinical presentation of DIPG and compatible MRI with approximately 2/3 of the
pons included. Subject should be ? 2 weeks and ? 10 weeks post standard focal
radiotherapy (ie, dose of 5400 to 5960 cGy and maximum dexamethasone of 1 mg/m2/day)

4. At the time of registration, subjects must have recovered from the toxic effects of
previous treatments, as determined by the treating physician.

1. Targeted agents, including small-molecular tyrosine kinase inhibitors: 2 weeks

2. Other cytotoxic agents: 3 weeks

3. Nitrosoureas: 6 weeks

4. Monoclonal antibody immunotherapies (eg, PD-1, CTLA-4): 6 weeks

5. Vaccine-based and/or viral therapy: 3 months

5. On a stable or decreasing dose of dexamethasone for the previous 7 days

6. Able to undergo standard MRI scans with contrast agent before enrollment and after

7. Have age-appropriate functional performance:

1. Lansky score ? 50 or

2. Karnofsky score > 50 or

3. Eastern Cooperative Oncology Group (ECOG) score ? 2

8. Have adequate bone marrow reserves and liver and kidney function, as assessed by the
following laboratory requirements:

1. Hemoglobin ? 8 g/L

2. Absolute lymphocyte count ? 500/mm3

3. Absolute neutrophil count ? 1000/mm3

4. Platelets ? 100,000/mm3 (untransfused [> 5 days] without growth factors)

5. Serum creatinine ? 1.5 x upper limit of normal (ULN) for age

6. Aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5 x ULN for age

7. Total bilirubin < 1.5 x ULN for age

8. International normalized ratio (INR) and activated thromboplastin time within
normal institutional limits

9. Male and female subjects of childbearing potential must agree to use a highly reliable
method of birth control (expected failure rate < 1% per year) from the Screening Visit
through 28 days after the last dose of study drug. Women of childbearing potential
must have a negative pregnancy test at screening.

Exclusion Criteria:

1. Radiotherapy treatment prior to the first veledimex dose:

1. Focal radiation ? 4 weeks

2. Whole-brain radiation ? 6 weeks

3. Cranio-spinal radiation ? 12 weeks NOTE: Subjects in Arm 2 (ie, with DIPG) must
be ? 2 weeks and ? 10 weeks after standard focal radiotherapy (dose of 5400 to
5960 cGy and maximum dexamethasone of 1 mg/m2/day)

2. Subjects with clinically significant increased intracranial pressure (eg, impending
herniation or requirement for immediate palliative treatment) or uncontrolled seizures

3. Subjects whose body surface area (BSA) would expose them to < 75% or > 125% of the
target dose

4. Known immunosuppressive disease, autoimmune condition, and/or chronic viral infection
(eg, human immunodeficiency virus [HIV], hepatitis)

5. Use of systemic antibacterial, antifungal, or antiviral medications for the treatment
of acute clinically significant infection within 2 weeks of first veledimex dose.
Concomitant therapy for chronic infections is not allowed. Subjects must be afebrile
prior to Ad-RTS-hIL-12 injection; only prophylactic antibiotic use is allowed

6. Use of enzyme-inducing antiepileptic drugs (EIAEDs) within 7 days prior to the first
dose of study drug

7. Other concurrent clinically active malignant disease, requiring treatment

8. Nursing or pregnant females

9. Prior exposure to veledimex

10. Use of medications that induce, inhibit, or are substrates of cytochrome p450 (CYP450)
3A4 within 7 days prior to veledimex

11. Use of heparin or acetylsalicylic acid (ASA)

12. Presence of any contraindication for a neurosurgical procedure

13. Unstable or clinically significant concurrent medical condition
LinksPermanent Link to THIS page:      |      Link to official listing
Chicago, Illinois
Facility: Lurie Children's Hospital of Chicago
Contact: Debra Tice Phone: 312-227-4090
Click HERE to send email to this center

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557

Website Design By
World Wide Websites